Bicycle Therapeutics Dirección
Dirección controles de criterios 4/4
El CEO de Bicycle Therapeutics es Kevin Lee , nombrado en Sep 2015, tiene una permanencia de 9.17 años. compensación anual total es $5.54M, compuesta por 12.8% salario y 87.2% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.37% de las acciones de la empresa, por valor de $6.00M. La antigüedad media del equipo directivo y de la junta directiva es de 2.8 años y 5.3 años, respectivamente.
Información clave
Kevin Lee
Chief Executive Officer (CEO)
US$5.5m
Compensación total
| Porcentaje del salario del CEO | 12.8% |
| Permanencia del CEO | 9.2yrs |
| Participación del CEO | 0.4% |
| Permanencia media de la dirección | 2.8yrs |
| Promedio de permanencia en la Junta Directiva | 5.3yrs |
Actualizaciones recientes de la dirección
Recent updates
Bicycle Therapeutics plc (NASDAQ:BCYC) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year
Nov 03
Bicycle Therapeutics (NASDAQ:BCYC) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Oct 23Bicycle Therapeutics Is Looking Increasingly Attractive
Aug 20Bicycle Therapeutics Boosts Balance Sheet To Navigate Data Desert
May 24Shareholders May Not Be So Generous With Bicycle Therapeutics plc's (NASDAQ:BCYC) CEO Compensation And Here's Why
May 10Analysts' Revenue Estimates For Bicycle Therapeutics plc (NASDAQ:BCYC) Are Surging Higher
May 04Does Bicycle Therapeutics (NASDAQ:BCYC) Have A Healthy Balance Sheet?
Apr 19Bicycle: 2nd Half Of 2024 Data Could Provide Significant Inflection Point
Mar 12Bicycle Therapeutics (NASDAQ:BCYC) Is Using Debt Safely
Jan 04Newsflash: Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Revenue Forecasts
Nov 07The Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Sales Forecasts
May 14Industry Analysts Just Upgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Revenue Forecasts By 26%
Mar 31Is Bicycle Therapeutics (NASDAQ:BCYC) Using Debt In A Risky Way?
Mar 09Time To Worry? Analysts Just Downgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Outlook
Nov 08Bicycle Therapeutics: Exploring An Intriguing Developmental Platform
Oct 08Bicycle Therapeutics initiated Outperform at Cowen citing drug platform
Aug 31Bicycle to get $10M as Genentech uses option for new program under cancer drug collaboration
Jul 12Is Bicycle Therapeutics (NASDAQ:BCYC) Weighed On By Its Debt Load?
Jul 10Bicycle Therapeutics: Promising Early-Stage Cancer Drug Developer
Jul 05Bicycle Therapeutics: Trying To Catch This Falling Knife
Apr 17Is Bicycle Therapeutics (NASDAQ:BCYC) A Risky Investment?
Apr 11Bicycle Therapeutics: A Buy Ahead Of AACR Presentation
Mar 25Bicycle Therapeutics: An Oncology Play With Big Potential
Feb 28Bicycle Therapeutics (NASDAQ:BCYC) Has Debt But No Earnings; Should You Worry?
Nov 07Bicycle Therapeutics: Scaffolding Short Linear Peptides Into Bicycles
Aug 25The Consensus EPS Estimates For Bicycle Therapeutics plc (NASDAQ:BCYC) Just Fell Dramatically
Aug 07News Flash: Analysts Just Made A Sizeable Upgrade To Their Bicycle Therapeutics plc (NASDAQ:BCYC) Forecasts
May 08Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$166m |
| Jun 30 2024 | n/a | n/a | -US$165m |
| Mar 31 2024 | n/a | n/a | -US$168m |
| Dec 31 2023 | US$6m | US$710k | -US$181m |
| Sep 30 2023 | n/a | n/a | -US$162m |
| Jun 30 2023 | n/a | n/a | -US$140m |
| Mar 31 2023 | n/a | n/a | -US$124m |
| Dec 31 2022 | US$9m | US$673k | -US$113m |
| Sep 30 2022 | n/a | n/a | -US$101m |
| Jun 30 2022 | n/a | n/a | -US$87m |
| Mar 31 2022 | n/a | n/a | -US$78m |
| Dec 31 2021 | US$4m | US$677k | -US$67m |
| Sep 30 2021 | n/a | n/a | -US$66m |
| Jun 30 2021 | n/a | n/a | -US$62m |
| Mar 31 2021 | n/a | n/a | -US$56m |
| Dec 31 2020 | US$3m | US$592k | -US$51m |
| Sep 30 2020 | n/a | n/a | -US$38m |
| Jun 30 2020 | n/a | n/a | -US$37m |
| Mar 31 2020 | n/a | n/a | -US$35m |
| Dec 31 2019 | US$4m | US$517k | -US$31m |
| Sep 30 2019 | n/a | n/a | -US$33m |
| Jun 30 2019 | n/a | n/a | -US$31m |
| Mar 31 2019 | n/a | n/a | -US$26m |
| Dec 31 2018 | US$818k | US$386k | -US$22m |
Compensación vs. Mercado: La compensación total ($USD5.54M) de Kevin está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD5.64M).
Compensación vs. Ingresos: La compensación de Kevin ha sido consistente con los resultados de la empresa en el último año.
CEO
Kevin Lee (56 yo)
9.2yrs
Permanencia
US$5,540,400
Compensación
Dr. Kevin Lee, M.B.A., Ph D., has been Chief Executive Officer of Bicycle Therapeutics plc since September 2015. Dr. Lee joined Bicycle Therapeutics from Pfizer where he served as Senior Vice President and...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Executive Director | 9.2yrs | US$5.54m | 0.37% $ 6.0m | |
| Co-Founder & Non-Executive Director | no data | US$477.04k | 0.24% $ 3.8m | |
| Chief Financial Officer | 1.3yrs | US$2.88m | sin datos | |
| Chief Development Officer | 1.7yrs | US$2.82m | 0% $ 0 | |
| Scientific Founder | no data | sin datos | sin datos | |
| Chief Operating Officer | 2.8yrs | US$5.98m | 0.024% $ 393.5k | |
| Senior VP | 1.4yrs | sin datos | 0.0037% $ 60.0k | |
| Chief Technology Officer | 2.8yrs | US$3.07m | 0.073% $ 1.2m | |
| Senior Vice President of Investor Relations and Corporate Communications | no data | sin datos | sin datos | |
| General Counsel | 4.6yrs | sin datos | sin datos | |
| Head of Clinical and Project Management | 8.5yrs | sin datos | sin datos | |
| Senior VP of Pre-Clinical Development | 6yrs | sin datos | sin datos |
2.8yrs
Permanencia media
55.5yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de BCYC se considera experimentado (2.8 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Executive Director | 9.2yrs | US$5.54m | 0.37% $ 6.0m | |
| Co-Founder & Non-Executive Director | no data | US$477.04k | 0.24% $ 3.8m | |
| Chairman of Scientific Advisory Board | 6.5yrs | sin datos | sin datos | |
| Non-Executive Chairman | 5.7yrs | US$1.06m | 0.031% $ 504.4k | |
| Independent Non-Executive Director | 3.7yrs | US$482.29k | 0.016% $ 252.2k | |
| Independent Non-Executive Director | 5.3yrs | US$526.91k | 0.016% $ 252.2k | |
| Member of Scientific Advisory Board | 4.1yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 4.1yrs | sin datos | sin datos | |
| Independent Non-Executive Director | 5.3yrs | US$495.41k | 0.016% $ 252.2k | |
| Member of Scientific Advisory Board | 6.5yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 4.1yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 4.1yrs | sin datos | sin datos |
5.3yrs
Permanencia media
64yo
Promedio de edad
Junta con experiencia: La junta directiva de BCYC se considera experimentada (5.3 años de antigüedad promedio).